Senolytic therapy in mild Alzheimer’s disease shows safety in phase I trial

Senolytic therapy in mild Alzheimer’s disease shows safety in phase I trial

In a recent study published in Nature Medicine, researchers conducted the phase 1 trial of orally-administered senolytic therapy comprising quercetin (Q) and dasatinib (D) for symptomatic and early-stage Alzheimer’s disease (AD) patients. … [read more]

Related News Stories:

  1. Alzheimer’s drug reduces plaques, slows disease progression: full results
  2. Fructose Linked to Alzheimer’s: Study
  3. COVID-19 vaccine effective against hospitalization from Omicron variant
  4. Long-term gastrointestinal outcomes of COVID-19
  5. This highly infectious disease is similar to Ebola, but what is Marburg virus disease? Is there a vaccine?
  6. Long COVID is defined by these 12 symptoms, new study finds
  7. Scientists discover gene therapy provides neuroprotection to prevent glaucoma vision loss
  8. Link between obstructive sleep apnea and early cognitive decline found
  9. Vagus nerve dysfunction has a central pathogenic role in the pathophysiology of the post-COVID condition
  10. Higher urine-to-plasma urea ratio reflects heightened risk of chronic kidney disease (CKD) progression
Find Weird and Wonderful Books at AbeBooks
Study on cause of Alzheimer’s turns established theory on its head

Study on cause of Alzheimer’s turns established theory on its head

Alzheimer’s drug reduces plaques, slows disease progression: full results

Alzheimer’s drug reduces plaques, slows disease progression: full results

Eating traditional Mediterranean-type diet may help reduce dementia risk

Eating traditional Mediterranean-type diet may help reduce dementia risk

Fructose Linked to Alzheimer’s: Study

Fructose Linked to Alzheimer’s: Study

Mushrooms Magnify Memory by Boosting Nerve Growth

Mushrooms Magnify Memory by Boosting Nerve Growth

Leave a Reply

Your email address will not be published. Required fields are marked *